Whales with a lot of money to spend have taken a noticeably bearish stance on Sarepta Therapeutics.
Looking at options history for Sarepta Therapeutics SRPT we detected 14 trades.
If we consider the specifics of each trade, it is accurate to state that 35% of the investors opened trades with bullish expectations and 50% with bearish.
From the overall spotted trades, 5 are puts, for a total amount of $374,000 and 9, calls, for a total amount of $1,862,920.
Projected Price Targets
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $155.0 to $180.0 for Sarepta Therapeutics over the last 3 months.
Volume & Open Interest Trends
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Sarepta Therapeutics's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Sarepta Therapeutics's substantial trades, within a strike price spectrum from $155.0 to $180.0 over the preceding 30 days.
Sarepta Therapeutics Option Volume And Open Interest Over Last 30 Days
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SRPT | CALL | TRADE | BULLISH | 08/16/24 | $4.5 | $2.0 | $3.6 | $175.00 | $1.4M | 6.1K | 974 |
| SRPT | PUT | TRADE | NEUTRAL | 01/16/26 | $26.2 | $22.3 | $24.2 | $155.00 | $121.0K | 0 | 50 |
| SRPT | CALL | TRADE | BULLISH | 07/19/24 | $0.55 | $0.2 | $0.55 | $180.00 | $91.3K | 2.3K | 347 |
| SRPT | CALL | SWEEP | BULLISH | 08/16/24 | $3.2 | $3.1 | $3.1 | $175.00 | $83.3K | 6.1K | 271 |
| SRPT | PUT | SWEEP | BEARISH | 07/19/24 | $18.0 | $16.1 | $18.0 | $170.00 | $72.0K | 69 | 0 |
About Sarepta Therapeutics
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.
Having examined the options trading patterns of Sarepta Therapeutics, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
Present Market Standing of Sarepta Therapeutics
- Trading volume stands at 875,313, with SRPT's price down by -1.27%, positioned at $156.06.
- RSI indicators show the stock to be may be overbought.
- Earnings announcement expected in 35 days.
Expert Opinions on Sarepta Therapeutics
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $191.6.
- Maintaining their stance, an analyst from BMO Capital continues to hold a Outperform rating for Sarepta Therapeutics, targeting a price of $170.
- An analyst from RBC Capital has decided to maintain their Sector Perform rating on Sarepta Therapeutics, which currently sits at a price target of $182.
- Consistent in their evaluation, an analyst from Leerink Partners keeps a Outperform rating on Sarepta Therapeutics with a target price of $230.
- An analyst from Citigroup downgraded its action to Neutral with a price target of $176.
- Consistent in their evaluation, an analyst from Morgan Stanley keeps a Overweight rating on Sarepta Therapeutics with a target price of $200.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Sarepta Therapeutics, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
